Pages that link to "Q52884043"
Jump to navigation
Jump to search
The following pages link to The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. (Q52884043):
Displaying 50 items.
- National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The 2014 Clinical Trial Design Working Group Report (Q26827651) (← links)
- Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C- (Q27021322) (← links)
- A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus (Q28254310) (← links)
- Omega-3 in SLE: a double-blind, placebo-controlled randomized clinical trial of endothelial dysfunction and disease activity in systemic lupus erythematosus (Q30409882) (← links)
- Lipid anti-lipid antibody responses correlate with disease activity in systemic lupus erythematosus (Q30588683) (← links)
- Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). (Q30832522) (← links)
- A meta-analysis of public microarray data identifies gene regulatory pathways deregulated in peripheral blood mononuclear cells from individuals with Systemic Lupus Erythematosus compared to those without (Q31142463) (← links)
- Identification of a urinary proteomic signature for lupus nephritis in children (Q33300680) (← links)
- Initial validation of a novel protein biomarker panel for active pediatric lupus nephritis (Q33409400) (← links)
- Validation of the Spanish, Portuguese and French versions of the Lupus Damage Index questionnaire: data from North and South America, Spain and Portugal (Q33504486) (← links)
- A prospective study of psychiatric disorder and cognitive function in systemic lupus erythematosus (Q33566318) (← links)
- Investigation of the prevalence and clinical associations of antibodies to human fibronectin in systemic lupus erythematosus (Q33567006) (← links)
- Further validation of the BILAG disease activity index in patients with systemic lupus erythematosus (Q33579349) (← links)
- Cell-bound complement biomarkers for systemic lupus erythematosus: from benchtop to bedside (Q33723371) (← links)
- Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: a multicenter clinical study (Q33767123) (← links)
- The use of immunosuppressive and cytotoxic drugs in non-malignant disease (Q34010757) (← links)
- Minimal clinically important differences of disease activity indices in childhood-onset systemic lupus erythematosus. (Q34046983) (← links)
- Clinical and immunologic manifestations of mixed connective tissue disease in a Miami population compared to a Midwestern US Caucasian population (Q34056359) (← links)
- Serological and genetic characterization of a human monoclonal immunoglobulin G anti-DNA idiotype (Q34141241) (← links)
- Prospective validation of the provisional criteria for the evaluation of response to therapy in childhood-onset systemic lupus erythematosus (Q34157817) (← links)
- Data quality challenges in systemic lupus erythematosus trials: how can this be optimized? (Q34267149) (← links)
- Serum levels of autoantibodies against C-reactive protein correlate with renal disease activity and response to therapy in lupus nephritis (Q34413203) (← links)
- Pharmacokinetics and pharmacodynamics of mycophenolic acid and their relation to response to therapy of childhood-onset systemic lupus erythematosus (Q34494943) (← links)
- Toward the development of criteria for global flares in juvenile systemic lupus erythematosus (Q34626276) (← links)
- Neutrophil gelatinase-associated lipocalin is a predictor of the course of global and renal childhood-onset systemic lupus erythematosus disease activity (Q34720014) (← links)
- Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus (Q34897437) (← links)
- Underexpression of mitochondrial-DNA encoded ATP synthesis-related genes and DNA repair genes in systemic lupus erythematosus (Q35093017) (← links)
- IgG anti-apolipoprotein A-1 antibodies in patients with systemic lupus erythematosus are associated with disease activity and corticosteroid therapy: an observational study (Q35162593) (← links)
- Anti-factor Xa antibodies in patients with antiphospholipid syndrome and their effects upon coagulation assays (Q35194106) (← links)
- Preliminary criteria for global flares in childhood-onset systemic lupus erythematosus (Q35199345) (← links)
- Preliminary test of the LFA rapid evaluation of activity in lupus (LFA-REAL): an efficient outcome measure correlates with validated instruments (Q35229292) (← links)
- Assessment of patients with idiopathic inflammatory myopathies and isolated creatin-kinase elevation. (Q35281980) (← links)
- Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus (Q35555256) (← links)
- How to monitor SLE in routine clinical practice (Q35555460) (← links)
- Raised levels of interleukin 6 in systemic lupus erythematosus correlate with anaemia (Q35555688) (← links)
- Systemic lupus erythematosus in a multiethnic cohort: LUMINA XXXV. Predictive factors of high disease activity over time (Q35637820) (← links)
- Treatment of lupus nephritis with abatacept: the Abatacept and Cyclophosphamide Combination Efficacy and Safety Study (Q35927877) (← links)
- B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response (Q35954653) (← links)
- Safety and efficacy of hCDR1 (Edratide) in patients with active systemic lupus erythematosus: results of phase II study (Q35960478) (← links)
- Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial (Q35993027) (← links)
- B-cell numbers and phenotype at clinical relapse following rituximab therapy differ in SLE patients according to anti-dsDNA antibody levels (Q36049625) (← links)
- Renal expression and serum levels of high mobility group box 1 protein in lupus nephritis (Q36085036) (← links)
- Urine metabolome profiling of immune-mediated inflammatory diseases (Q36127459) (← links)
- Impact of standard of care treatments and disease variables on outcomes in systemic lupus erythematosus trials: analysis from the Lupus Foundation of America Collective Data Analysis Initiative (Q36154537) (← links)
- Hydroxychloroquine is associated with impaired interferon-alpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus (Q36246166) (← links)
- Functional Characterization of Autoantibodies against Complement Component C3 in Patients with Lupus Nephritis. (Q36283294) (← links)
- Belimumab in systemic lupus erythematosus: an update for clinicians (Q36443781) (← links)
- Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus and lupus nephritis who are refractory to conventional therapy (Q36518986) (← links)
- Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group repor (Q36554724) (← links)
- Effects of conventional immunosuppressive treatment on CD244 (CD28null) and FOXP3 T cells in the inflamed muscle of patients with polymyositis and dermatomyositis (Q36758692) (← links)